ISG15 is upregulated in respiratory syncytial virus infection and reduces virus growth through protein ISGylation

Journal of Virology

Volumn 90, Issue 7, 2016, Pages 3428-3438

  González Sanz, Rubén ^a,b   Mata, Manuel ^b,c   Bermejo Martín, Jesús ^d   Álvarez, Amparo ^a   Cortijo, Julio ^b,c   Melero, José A ^a,b   Martínez, Isidoro ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON STIMULATED GENE 15 PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; CYTOKINE; ISG15 PROTEIN, HUMAN; PROTEINASE; SMALL INTERFERING RNA; UBE1L PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; USP18 PROTEIN, HUMAN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIROGENESIS; VIRUS INHIBITION; VIRUS LOAD; VIRUS TITRATION; EPITHELIUM CELL; GENETICS; HELA CELL LINE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; METABOLISM; PROTEIN PROCESSING; RESPIRATORY TRACT INFECTION; RNA INTERFERENCE; TUMOR CELL LINE; VIROLOGY;

CELL LINE, TUMOR; CYTOKINES; ENDOPEPTIDASES; EPITHELIAL CELLS; HELA CELLS; HUMANS; IMMUNITY, INNATE; INFANT; PROTEIN PROCESSING, POST-TRANSLATIONAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINS;

EID: 84960976822     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02695-15     Document Type: Article

References (66)

1. Collins PL, Karron RA. 2013. Respiratory syncytial virus and metapneumovirus, p 1087-1123. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82:2040-2055. http://dx.doi.org/10.1128/JVI.01625-07.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. NEngl J Med 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
4. Welliver RC, Sr. 2008. The immune response to respiratory syncytial virus infection: friend or foe? Clin Rev Allergy Immunol 34:163-173. http://dx.doi.org/10.1007/s12016-007-8033-2.
5. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
6. Fensterl V, Sen GC. 2009. Interferons and viral infections. Biofactors 35:14-20. http://dx.doi.org/10.1002/biof.6.
7. Sen GC, Sarkar SN. 2007. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr Top Microbiol Immunol 316:233-250.
8. Schmid S, Mordstein M, Kochs G, Garcia-Sastre A, Tenoever BR. 2010. Transcription factor redundancy ensures induction of the antiviral state. J Biol Chem 285:42013-42022. http://dx.doi.org/10.1074/jbc. M110.165936.
9. Sung RY, Yin J, Oppenheimer SJ, Tam JS, Lau J. 1993. Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a. Arch Dis Child 69:440-442. http://dx.doi.org/10.1136/adc.69.4.440.
10. McIntosh K. 1978. Interferon in nasal secretions from infants with viral respiratory tract infections. J Pediatr 93:33-36.
11. Hall CB, Douglas RG, Jr, Simons RL, Geiman JM. 1978. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr 93:28-32. http://dx.doi.org/10.1016/S0022-3476(78)80594-0.
12. Gao L, Yu S, Chen Q, Duan Z, Zhou J, Mao C, Yu D, Zhu W, Nie J, Hou Y. 2010. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine 28:4445-4451. http://dx.doi.org/10.1016/j.vaccine.2010.03.062.
13. Barik S. 2013. Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Curr Top Microbiol Immunol 372:173-191. http://dx.doi.org/10.1007/978-3-642-38919-1_9.
14. Swedan S, Andrews J, Majumdar T, Musiyenko A, Barik S. 2011. Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location. J Virol 85:10090-10100. http://dx.doi.org/10.1128/JVI.00413-11.
15. Lo MS, Brazas RM, Holtzman MJ. 2005. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 79:9315-9319. http://dx.doi.org/10.1128/JVI.79.14.9315-9319.2005.
16. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. 2004. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J Virol 78:4363-4369. http://dx.doi.org/10.1128/JVI.78.8.4363-4369.2004.
17. Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA. 2007. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol 81:3428-3436. http://dx.doi.org/10.1128/JVI.02303-06.
18. Ling Z, Tran KC, Teng MN. 2009. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol 83:3734-3742. http://dx.doi.org/10.1128/JVI.02434-08.
19. Swedan S, Musiyenko A, Barik S. 2009. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol 83:9682-9693. http://dx.doi.org/10.1128/JVI.00715-09.
20. Martinez I, Lombardia L, Garcia-Barreno B, Dominguez O, Melero JA. 2007. Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. J Gen Virol 88: 570-581. http://dx.doi.org/10.1099/vir.0.82187-0.
21. Loeb KR, Haas AL. 1992. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267:7806-7813.
22. Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O'Guin AK, Schmidt RE, Levine B, Virgin HWt. 2005. Identification of interferonstimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 79:13974-13983. http://dx.doi.org/10.1128/JVI.79.22.13974-13983.2005.
23. Zhang D, Zhang DE. 2011. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 31:119-130. http://dx.doi.org/10.1089/jir.2010.0110.
24. Yuan W, Krug RM. 2001. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 20:362-371. http://dx.doi.org/10.1093/emboj/20.3.362.
25. Kim KI, Giannakopoulos NV, Virgin HW, Zhang DE. 2004. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol 24:9592-9600. http://dx.doi.org/10.1128/MCB.24.21.9592-9600.2004.
26. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, Huibregtse JM, Krug RM. 2004. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc Natl Acad Sci U S A 101:7578-7582. http://dx.doi.org/10.1073/pnas.0402528101.
27. Dastur A, Beaudenon S, Kelley M, Krug RM, Huibregtse JM. 2006. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J Biol Chem 281:4334-4338. http://dx.doi.org/10.1074/jbc. M512830200.
28. Takeuchi T, Inoue S, Yokosawa H. 2006. Identification and Herc5-mediated ISGylation of novel target proteins. Biochem Biophys Res Commun 348:473-477. http://dx.doi.org/10.1016/j.bbrc.2006.07.076.
29. Liu LQ, Ilaria R, Jr, Kingsley PD, Iwama A, van Etten RA, Palis J, Zhang DE. 1999. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 19:3029-3038. http://dx.doi.org/10.1128/MCB.19.4.3029.
30. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. 2002. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 277:9976-9981. http://dx.doi.org/10.1074/jbc. M109078200.
31. Durfee LA, Lyon N, Seo K, Huibregtse JM. 2010. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol Cell 38:722-732. http://dx.doi.org/10.1016/j.molcel.2010.05.002.
32. Bogunovic D, Boisson-Dupuis S, Casanova JL. 2013. ISG15: leading a double life as a secreted molecule. Exp Mol Med 45:e18. http://dx.doi.org/10.1038/emm.2013.36.
33. Campbell JA, Lenschow DJ. 2013. Emerging roles for immunomodulatory functions of free ISG15. J Interferon Cytokine Res 33:728-738. http://dx.doi.org/10.1089/jir.2013.0064.
34. Okumura A, Pitha PM, Harty RN. 2008. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci U S A 105:3974-3979. http://dx.doi.org/10.1073/pnas.0710629105.
35. Werneke SW, Schilte C, Rohatgi A, Monte KJ, Michault A, Arenzana-Seisdedos F, Vanlandingham DL, Higgs S, Fontanet A, Albert ML, Lenschow DJ. 2011. ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS Pathog 7:e1002322. http://dx.doi.org/10.1371/journal.ppat.1002322.
36. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, WolffT, Osiak A, Levine B, Schmidt RE, Garcia-Sastre A, Leib DA, Pekosz A, Knobeloch KP, Horak I, Virgin HWT. 2007. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A 104:1371-1376. http://dx.doi.org/10.1073/pnas.0607038104.
37. Okumura A, Lu G, Pitha-Rowe I, Pitha PM. 2006. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A 103:1440-1445. http://dx.doi.org/10.1073/pnas.0510518103.
38. Ma XZ, Bartczak A, Zhang J, He W, Shalev I, Smil D, Chen L, Phillips J, Feld JJ, Selzner N, Levy G, McGilvray I. 2014. Protein interferonstimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. J Virol 88:6195-6204. http://dx.doi.org/10.1128/JVI.03801-13.
39. Guerra S, Caceres A, Knobeloch KP, Horak I, Esteban M. 2008. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 4:e1000096. http://dx.doi.org/10.1371/journal.ppat.1000096.
40. Yanguez E, Garcia-Culebras A, Frau A, Llompart C, Knobeloch KP, Gutierrez-Erlandsson S, Garcia-Sastre A, Esteban M, Nieto A, Guerra S. 2013. ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog 9:e1003632. http://dx.doi.org/10.1371/journal.ppat.1003632.
41. Hishiki T, Han Q, Arimoto K, Shimotohno K, Igarashi T, Vasudevan SG, Suzuki Y, Yamamoto N. 2014. Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication. Biochem Biophys Res Commun 448:95-100. http://dx.doi.org/10.1016/j.bbrc.2014.04.081.
42. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. 2010. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol 91:382-388. http://dx.doi.org/10.1099/vir.0.015388-0.
43. Broering R, Zhang X, Kottilil S, Trippler M, Jiang M, Lu M, Gerken G, Schlaak JF. 2010. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 59:1111-1119. http://dx.doi.org/10.1136/gut.2009.195545.
44. Real CI, Megger DA, Sitek B, Jahn-Hofmann K, Ickenstein LM, John MJ, Walker A, Timm J, Kuhlmann K, Eisenacher M, Meyer HE, Gerken G, Broering R, Schlaak JF. 2013. Identification of proteins that mediate the pro-viral functions of the interferon stimulated gene 15 in hepatitis C virus replication. Antiviral Res 100:654-661. http://dx.doi.org/10.1016/j.antiviral.2013.10.009.
45. Eduardo-Correia B, Martinez-Romero C, Garcia-Sastre A, Guerra S. 2014. ISG15 is counteracted by vaccinia virus E3 protein and controls the proinflammatory response against viral infection. J Virol 88:2312-2318. http://dx.doi.org/10.1128/JVI.03293-13.
46. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
47. Mukherjee S, Lukacs NW. 2013. Innate immune responses to respiratory syncytial virus infection. Curr Top Microbiol Immunol 372:139-154. http://dx.doi.org/10.1007/978-3-642-38919-1_7.
48. Mbiguino A, Menezes J. 1991. Purification of human respiratory syncytial virus: superiority of sucrose gradient over Percoll, Renografin, and metrizamide gradients. J Virol Methods 31:161-170. http://dx.doi.org/10.1016/0166-0934(91)90154-R.
49. Martinez I, Dopazo J, Melero JA. 1997. Antigenic structure of the human respiratory syncytial virusGglycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78:2419-2429. http://dx.doi.org/10.1099/0022-1317-78-10-2419.
50. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA. 1989. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63:925-932.
51. Kim Y, Kweon J, Kim A, Chon JK, Yoo JY, Kim HJ, Kim S, Lee C, Jeong E, Chung E, Kim D, Lee MS, Go EM, Song HJ, Kim H, Cho N, Bang D, Kim JS. 2013. A library of TAL effector nucleases spanning the human genome. Nat Biotechnol 31:251-258. http://dx.doi.org/10.1038/nbt.2517.
52. Cortijo J, Milara J, Mata M, Donet E, Gavara N, Peel SE, Hall IP, Morcillo EJ. 2010. Nickel induces intracellular calcium mobilization and pathophysiological responses in human cultured airway epithelial cells. Chem Biol Interact 183:25-33. http://dx.doi.org/10.1016/j.cbi.2009.09.011.
53. Chung HL, Kim WT, Kim JK, Choi EJ, Lee JH, Lee GH, Kim SG. 2005. Relationship between atopic status and nasal interleukin 10 and 11 levels in infants with respiratory syncytial virus bronchiolitis. Ann Allergy Asthma Immunol 94:267-272. http://dx.doi.org/10.1016/S1081-1206(10)61307-5.
54. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, Shuai K, Zhang DE. 2006. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 25:2358-2367. http://dx.doi.org/10.1038/sj.emboj.7601149.
55. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, Volpi S, Li Z, Sanal O, Mansouri D, Tezcan I, Rice GI, Chen C, Mansouri N, Mahdaviani SA, Itan Y, Boisson B, Okada S, Zeng L, Wang X, Jiang H, Liu W, Han T, Liu D, Ma T, Wang B, Liu M, Liu JY, Wang QK, Yalnizoglu D, Radoshevich L, Uze G, Gros P, Rozenberg F, Zhang SY, Jouanguy E, Bustamante J, Garcia-Sastre A, Abel L, Lebon P, Notarangelo LD, Crow YJ, Boisson-Dupuis S, Casanova JL, Pellegrini S. 2015. Human intracellular ISG15 prevents interferon-alpha/beta overamplification and auto-inflammation. Nature 517:89-93. http://dx.doi.org/10.1038/nature13801.
56. Rodriguez MR, Monte K, Thackray LB, Lenschow DJ. 2014. ISG15 functions as an interferon-mediated antiviral effector early in the murine norovirus life cycle. J Virol 88:9277-9286. http://dx.doi.org/10.1128/JVI.01422-14.
57. Morales DJ, Lenschow DJ. 2013. The antiviral activities of ISG15. J Mol Biol 425:4995-5008. http://dx.doi.org/10.1016/j.jmb.2013.09.041.
58. Lenschow DJ. 2010. Antiviral properties of ISG15. Viruses 2:2154-2168. http://dx.doi.org/10.3390/v2102154.
59. Tang Y, Zhong G, Zhu L, Liu X, Shan Y, Feng H, Bu Z, Chen H, Wang C. 2010. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J Immunol 184:5777-5790. http://dx.doi.org/10.4049/jimmunol.0903588.
60. Zhao C, Hsiang TY, Kuo RL, Krug RM. 2010. ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells. Proc Natl Acad Sci U S A 107:2253-2258. http://dx.doi.org/10.1073/pnas.0909144107.
61. Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF, Zhu LH, Wang C. 2010. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol 30:2424-2436. http://dx.doi.org/10.1128/MCB.01466-09.
62. Ketscher L, Hannss R, Morales DJ, Basters A, Guerra S, Goldmann T, Hausmann A, Prinz M, Naumann R, Pekosz A, Utermohlen O, Lenschow DJ, Knobeloch KP. 2015. Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance. Proc Natl Acad Sci U S A 112:1577-1582. http://dx.doi.org/10.1073/pnas.1412881112.
63. Kohlmeier JE, Woodland DL. 2009. Immunity to respiratory viruses. Annu Rev Immunol 27:61-82. http://dx.doi.org/10.1146/annurev.immunol.021908.132625.
64. Goritzka M, Makris S, Kausar F, Durant LR, Pereira C, Kumagai Y, Culley FJ, Mack M, Akira S, Johansson C. 2015. Alveolar macrophagederived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J Exp Med 212:699-714. http://dx.doi.org/10.1084/jem.20140825.
65. Morales DJ, Monte K, Sun L, StruckhoffJJ, Agapov E, Holtzman MJ, Stappenbeck TS, Lenschow DJ. 2015. Novel mode of ISG15-mediated protection against influenza A virus and Sendai virus in mice. J Virol 89:337-349. http://dx.doi.org/10.1128/JVI.02110-14.
66. D'Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E, Jr, Borden EC. 1996. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 157:4100-4108.